MARIJN E. DEKKERS - 24 Sep 2021 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role
Director
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol
CERE
Transactions as of
24 Sep 2021
Transactions value $
$0
Form type
4
Filing time
28 Sep 2021, 16:10:16 UTC
Previous filing
20 Sep 2021
Next filing
14 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERE Common Stock Options Exercise +14,270 +50% 42,810 24 Sep 2021 Direct F1
holding CERE Common Stock 633,350 24 Sep 2021 See footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Restricted Stock Units Options Exercise $0 -14,270 -100% $0* 0 24 Sep 2021 Common Stock 14,270 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock.
F2 Shares held by Novalis LifeSciences Investments I, L.P., or Novalis LifeSciences. Marijn Dekkers, the Manager of the general partner of Novalis LifeSciences, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences.
F3 14,270 RSUs vested on September 24, 2021, the third anniversary of the vesting commencement date of September 24, 2018.